Cellibre is a manufacturing technology company that employs an organism-agnostic approach to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Its initial strategic focus is changing how natural, plant-based compounds are manufactured, targeting high-value natural products and bioactives to displace agricultural production. The company highlights industrial uses of natural products—including monomers that can be used to produce thermosetting resins, certain polymers, and energetics—and aims to enable domestic chemical production. Cellibre states its technologies achieve lower cost and higher quality than legacy production methods to improve supply‑chain resilience for customers and government partners. The recent $1.5 million Department of Defense award under the Distributed Bioindustrial Manufacturing Program (DBIMP) is intended to prepare commercialization of its manufacturing technologies to bolster domestic supply chains. Cellibre was founded in 2019 and is headquartered in San Diego, California. Cellibre is a San Diego, CA-based sustainable manufacturing technology company founded in 2017 that employs an organism-agnostic approach to turn cells into specialized, sustainable factories. The company’s platform is designed to manufacture globally significant products at scale, with an initial strategic focus on enabling the production of pharmaceutical-grade cannabinoids. Cellibre is led by founder and CEO Ben Chiarelli and founder and chief scientific officer Dr. Nicky Caiazza. In October 2021 the company closed an $11.5M Series A financing. The financing was led by Merida Capital Holdings with participation from the founders, Scott Gordon, Flatiron Venture Partners, L2V, Entourage Effect Capital, and Delta Emerald Ventures. Cellibre intends to use the proceeds to expand operations and broaden its business reach. Cellibre develops proprietary cells to enable production of pure, natural, pharmaceutical-grade cannabinoids through fermentation. The company uses an organism-agnostic approach to turn cells into specialized, sustainable factories for manufacturing globally significant products at scale. Its initial strategic focus is on deploying that expertise to enable pharmaceutical-grade cannabinoid production. Cellibre was founded in 2017 by CEO Ben Chiarelli and is based in San Diego, CA. The company intends to accelerate development of its cell platforms using newly raised funds. No operating metrics or revenue figures were disclosed in the article.

Total raised

$13M

Funding rounds

3

Latest round

Series A

Latest activity

Oct 2021